All In Biotech

Drug Trial Radar · NCT04732494

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) Versus Tislelizumab Plus Placebo as Second-Line Treatment in Patients With PD-L1 Tumor Area Positivity (TAP) ≥ 10% Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Jan 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Mar 31, 2021

Primary completion

Feb 1, 2023

Study completion Dec 26, 2023

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Feb 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Conditions

  • Esophageal Squamous Cell Carcinoma

Interventions

  • TislelizumabBiological

    Tislelizumab is a monoclonal antibody formulated for intravenous injection.

  • OciperlimabBiological

    Ociperlimab is a monoclonal antibody formulated for intravenous injection.

  • PlaceboDrug

    Ociperlimab placebo injection is a sterile, preservative-free solution for infusion formulated in the same buffer as ociperlimab active drug.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Assessed by the InvestigatorTime frame: Up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.

Locations

86 sites in 6 countries. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China

  • Heping Hospital Affiliated to Changzhi Medical College

    Changzhi, China

  • The First People's Hospital of Changzhou

    Changzhou, China

  • Fujian Cancer Hospital

    Fujian, China

  • The First Affiliated Hospital of Fujian Medical University

    Fujian, China

  • Zhongshan Hospital Xiamen University

    Fujian, China

  • Cancer Hospital of Shantou University Medical College

    Guangdong, China

  • Nanfang Hospital of Southern Medical University

    Guangdong, China

  • Sun Yat-sen University Cancer Center

    Guangdong, China

  • The First Affiliated Hospital of Guangzhou University of Chinese Medicine

    Guangdong, China

  • The Sixth Affiliated Hospital, Sun Yat-sen University

    Guangdong, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Guangxi, China

  • Hainan General Hospital

    Hainan, China

  • Affiliated Hospital of Hebei University

    Hebei, China

  • The Second Hospital of Anhui Medical University

    Hefei, China

  • Harbin Medical University Cancer Hospital

    Heilongjiang, China

  • Henan Cancer Hospital

    Henan, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Henan, China

  • Hubei Cancer Hospital

    Hubei, China

  • Xiangyang Central Hospital

    Hubei, China

  • Hunan Cancer Hospital

    Hunan, China

  • The First Affiliated Hospital of Nanchang University

    Jiangxi, China

  • The Second Affiliated Hospital of Nanchang University

    Jiangxi, China

  • Linyi Cancer Hospital

    Shandong, China

  • Weifang People's Hospital

    Shandong, China

  • Shanghai Chest Hospital

    Shanghai, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, China

  • Sichuan Provincial People's Hospital

    Sichuan, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China

  • Northern Jiangsu People's Hospital

    Yangzhou, China

  • Hangzhou Cancer Hospital

    Zhejiang, China

  • Hwa Mei Hospital, University of Chinese Academy of Sciences

    Zhejiang, China

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • Quanzhou First Hospital of Fujian Province

    Quanzhou, Fujian, China

  • First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • Lanzhou University Second Hospital

    Gansu, Gansu, China

  • Guangdong Provincial Hospital of Chinese Medicine

    Guangzhou, Guangdong, China

  • Meizhou Hospital Affiliated to Sun Yat-sen University

    Guangzhou, Guangdong, China

Showing 40 of 86 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.